Medicinal Chemistry Strategies to Reduce CYP2D6 Inhibitory Activity of Lead Candidates

Author(s): Bertrand Le Bourdonnec, Lara K. Leister

Journal Name: Current Medicinal Chemistry

Volume 16 , Issue 24 , 2009

Become EABM
Become Reviewer
Call for Editor


Among the various human cytochrome P450s (CYP450s) that catalyze the biotransformation of xenobiotics, CYP450 2D6 (CYP2D6) is one of the most important based on the number and wide variety of its drug substrates. CYP2D6 shows a high degree of interindividual variability, which is primarily due to the extensive genetic polymorphism that influences its expression and function. A number of drugs have been clinically implicated in major drug-drug interactions (DDI) via CYP2D6 inhibition. In order to avoid or minimize issues related to CYP2D6-mediated DDIs, pharmaceutical companies routinely screen for potential CYP2D6 liability of lead candidates in the early stage of the drug discovery process. This review summarizes the medicinal chemistry tactics employed to mitigate inhibitory activity at CYP2D6, identified through an extensive literature survey covering the 1998-2008 period.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [3093 - 3121]
Pages: 29
DOI: 10.2174/092986709788803033
Price: $65

Article Metrics

PDF: 31